CAM
CRSP icon

Congress Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Congress Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.15M Buy
111,230
+1,777
+2% +$95.9K 0.04% 257
2026
Q2 		$5.97M Buy
109,453
+1,082
+1% +$57K 0.04% 248
2026
Q1 		$5.16M Buy
108,371
+45,035
+71% +$2.38M 0.04% 245
2025
Q4 		$3.32M Sell
63,336
-4,774
-7% -$286K 0.02% 254
2025
Q3 		$4.41M Sell
68,110
-294
-0.4% -$16.9K 0.03% 238
2025
Q2 		$3.33M Buy
68,404
+102
+0.1% +$3.95K 0.02% 253
2025
Q1 		$2.32M Sell
68,302
-437
-0.6% -$18.5K 0.02% 265
2024
Q4 		$2.71M Buy
68,739
+2,971
+5% +$140K 0.02% 267
2024
Q3 		$3.09M Buy
65,768
+1,788
+3% +$90.7K 0.02% 255
2024
Q2 		$3.46M Sell
63,980
-625
-1% -$36.2K 0.02% 249
2024
Q1 		$4.4M Buy
64,605
+24,303
+60% +$1.74M 0.03% 231
2023
Q4 		$2.52M Buy
40,302
+42
+0.1% +$2.32K 0.02% 283
2023
Q3 		$1.83M Buy
+40,260
New +$2.08M 0.02% 282
2021
Q1 		– Sell
-16,695
Closed -$2.56M – 358
2020
Q4 		$2.56M Buy
16,695
+170
+1% +$20.1K 0.02% 228
2020
Q3 		$1.38M Hold
16,525
– – 0.02% 243
2020
Q2 		$1.21M Buy
16,525
+375
+2% +$21.9K 0.01% 250
2020
Q1 		$685K Hold
16,150
– – 0.01% 272
2019
Q4 		$984K Sell
16,150
-26,940
-63% -$1.47M 0.01% 281
2019
Q3 		$1.77M Hold
43,090
– – 0.02% 262
2019
Q2 		$2.03M Buy
43,090
+23,530
+120% +$940K 0.03% 269
2019
Q1 		$699K Buy
+19,560
New +$676K 0.01% 309

Other funds holding CRSP

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
HPBT
Hickory Point Bank & Trust Decatur, Illinois $166M AUM 19.36% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Congress Asset Management's CRSP Position: Q3 2026 in Review

Congress Asset Management increased its CRISPR Therapeutics (CRSP) stake by 1.6% in Q3 2026, buying an estimated $95.9K and bringing the position to 111,230 shares worth $6.15M. The position accounts for 0.04% of the portfolio, ranked #257.

Congress Asset Management first reported a position in CRSP in Q1 2019 and has held it in 21 quarters since. 13 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Congress Asset Management held 111,230 shares of CRISPR Therapeutics worth $6.15M as of Q3 2026.
  • Congress Asset Management bought 1,777 CRISPR Therapeutics shares in Q3 2026, an estimated $95.9K.
  • CRISPR Therapeutics made up 0.04% of Congress Asset Management's portfolio in Q3 2026, its #257 holding.
  • Congress Asset Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 21 quarters since.
  • 13 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.